NATCO Pharma Limited a pharmaceutical company that engages in the developing, manufacturing, and marketing of finished dosage formulations, active pharmaceutical ingredients (APIs), and intermediates.
Business Segments
The company operates through…
Analysis
Quality compounder
NATCO Pharma Limited earns the quality_compounder label: good underlying economics priced fairly, with no obvious bargain or excess.
On valuation, the picture is attractive. The owner-earnings multiple stands at 11.2×; owner earnings: the cash an owner could take out each year.
Growth is tepid; the safety picture is sturdy. The company scores 10/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.
360° rank · history
1007550250
Jan 202349
24
2023202420252026
All-time high
100
Jan 2024
All-time low
24
Jun 2026
Average rank
63
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
19
58
61
41
Price/Earnings
46
100
100
76
Price/Book
73
78
78
65
Dividend Yield
47
69
66
72
Value (overall)
54
85
83
75
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.